PCSK9 and osteoarthritis, knee: PCSK9-mediated LDL cholesterol, targeted by drugs such as evolocumab and alirocumab, also showed a suggestive relationship with OA of the hip or knee (OR = 0.915, 95%CI: 0.847 to 0.988, p = 0.023, q = 0.07) and knee osteoarthritis (OR = 0.901, 95%CI: 0.821 to 0.990, p = 0.03, q = 0.07).